Biotech Co. Investors Battle To Lead COVID-19 Vaccine Suit
Investors vying for the lead role in a proposed class action alleging San Francisco-headquartered biotechnology company Vaxart Inc. lied about its COVID-19 vaccine candidate traded jabs on Friday in competing responses...To view the full article, register now.
Already a subscriber? Click here to view full article